This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Essen, R. Articles by Weidinger, G. Search for Related Content PubMed PubMed Citation Articles by von Essen, R. Articles by Weidinger, G.

(Circulation. 1997;96:1482-1487.)
© 1997 American Heart Association, Inc.

Articles

Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty

Results of the VERAS Study

Rainer von Essen, MD; Ralf Ostermaier, MD; Eberhard Grube, MD; Wolfgang Mäurer, MD; Ulrich Tebbe, MD; Raimund Erbel, MD; Michael Roth, MD; Werner Oel, MD; Joachim Brom, PhD; Gottfried Weidinger, PhD; ; for the VERAS Investigators

From Stiftsklinik Augustinum (R. von E., R.O., M.R., W.O.), München; Krankenhaus Siegburg (E.G.); Klinikum Bayreuth (W.M.); Klinikum Lippe-Detmold (U.T.); Universitätsklinikum Essen (R.E.); and Sandoz (J.B., G.W.), Nürnberg, Germany.

Correspondence to Rainer von Essen, MD, Klinik für Innere Medizin, Stiftsklinik Augustinum, Wolkerweg 16, 81375 München, Germany.

Background The VERAS study (VErringerung der Re- stenoserate nach Angioplastie durch ein Somatostatin-analogon [Prevention of Restenosis Following Angioplasty With a Somatostatin Analogue]) was a placebo-controlled trial to evaluate the effects of octreotide for the prevention of restenosis after coronary angioplasty. Octreotide is a somatostatin analogue with antiproliferative properties on smooth muscle cell growth in vitro that limits myointimal thickening of arteries in balloon injury models.

Methods and Results Patients received either octreotide or placebo, starting 1 hour before angioplasty and continued for 3 weeks. The minimal luminal diameters before and after angioplasty and at 6-month follow-up were analyzed with a digital quantitative algorithm. Of the initial 274 patients recruited, 217 (108 in the octreotide group and 109 in the placebo group) could be analyzed after a complete 6-month evaluation: the minimal luminal diameters were 1.67±0.57 mm in the oc-treotide-treated group and 1.66±0.64 mm in the placebo group (two-paired P=.70), and the relative losses were 0.16±0.22 and 0.13±0.21 (two-paired P=.27). The restenosis rates were also identical in both treatment groups: final diameter stenosis 50% (34.3% versus 33.9%, two-paired P=1.0), loss of 50% of the initial gain (34.3% versus 33.9%, two-paired P=1.0), and absolute reduction of minimal luminal diameter >0.72 mm (29.6% versus 24.8%, two-paired P=.45). Likewise, there was no difference with regard to the incidence of clinical events (death, myocardial infarction, bypass operations, reintervention). Octreotide was well tolerated, with the exception of gastrointestinal side effects, which were three times more common than in the placebo group.

Conclusions Octreotide did not reduce the angiographically determined restenosis rate or the incidence of major clinical events after coronary angioplasty.

Key Words: angioplasty • restenosis • octreotide

This article has been cited by other articles:

				M. Y. Wells, H. Voute, M.-O. Lonchampt, C. Fisch, V. Boulifard, and P. Picaut Intimal Hyperplasia in Rats after Subcutaneous Injection of a Somatostatin Analog Toxicol Pathol, February 1, 2009; 37(2): 235 - 243. [Abstract] [Full Text] [PDF]

				P. Delafontaine, Y.-H. Song, and Y. Li Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 435 - 444. [Abstract] [Full Text]

				J. Frystyk, T. Ledet, N. Moller, A. Flyvbjerg, and H. Orskov Cardiovascular Disease and Insulin-Like Growth Factor I Circulation, August 20, 2002; 106(8): 893 - 895. [Full Text] [PDF]

				W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF]

				A. Bayes-Genis, C. A. Conover, and R. S. Schwartz The Insulin-Like Growth Factor Axis : A Review of Atherosclerosis and Restenosis Circ. Res., February 4, 2000; 86(2): 125 - 130. [Abstract] [Full Text] [PDF]

				A. Tiran, R. A. Tio, J. M. Ossewaarde, B. Tiran, P. den Heijer, T. H. The, and M. M. Wilders-Truschnig Coronary Angioplasty Induces Rise in Chlamydia pneumoniae-Specific Antibodies J. Clin. Microbiol., April 1, 1999; 37(4): 1013 - 1017. [Abstract] [Full Text]

				S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]